{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:14:08Z","timestamp":1793783648117,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.2119\/molmed.2015.00088","type":"journal-article","created":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T14:18:29Z","timestamp":1440598709000},"page":"389-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Karen M.","family":"Ashe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Budman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh S.","family":"Bangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Nietupski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Desnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald K.","family":"Scheule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,30]]},"reference":[{"key":"2101389_CR1","unstructured":"Desnick RJ, Ioannou YA, Eng CM. 150: \u03b1-Galactosidase A Deficiency: Fabry Disease. In: The Online Metabolic and Molecular Bases of Inherited Disease [Internet]. Valle D, et al. (eds.) McGraw-Hill, [New York]. Available from: https:\/\/doi.org\/ommbid.mhmedical.com\/content.aspx?bookid=474&sectionid=45374153"},{"key":"2101389_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transplant. 21:345\u2013354.","journal-title":"Nephrol. Dial. Transplant."},{"key":"2101389_CR3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, et al. (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 18:1547\u20131557.","journal-title":"J. Am. Soc. Nephrol."},{"key":"2101389_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, et al. (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann. Intern. Med. 146:77\u201386.","journal-title":"Ann. Intern. Med."},{"key":"2101389_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, et al. (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 75:65\u201374.","journal-title":"Am. J. Hum. Genet."},{"key":"2101389_CR6","doi-asserted-by":"publisher","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","volume":"2","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, et al. (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg. PLoS One. 2:e598.","journal-title":"PLoS One"},{"key":"2101389_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"CM Eng","year":"2001","unstructured":"Eng CM, et al. (2001) A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 68:711\u2013722.","journal-title":"Am. J. Hum. Genet."},{"key":"2101389_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease. N. Engl. J. Med. 345:9\u201316.","journal-title":"N. Engl. J. Med."},{"key":"2101389_CR9","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, et al. (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 62:1933\u20131946.","journal-title":"Kidney Int."},{"key":"2101389_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C Tondel","year":"2013","unstructured":"Tondel C, et al. (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J. Am. Soc. Nephrol. 24:137\u2013148.","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl 2","key":"2101389_CR11","doi-asserted-by":"publisher","first-page":"S243","DOI":"10.1016\/S0248-8663(10)70021-7","volume":"31","author":"M Dutsch","year":"2010","unstructured":"Dutsch M, Hilz MJ. (2010) Neurological complications in Fabry disease. Rev. Med. Interne. 31Suppl 2:S243\u2013S250.","journal-title":"Rev. Med. Interne."},{"key":"2101389_CR12","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","volume":"62","author":"MJ Hilz","year":"2004","unstructured":"Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M. (2004) Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology. 62:1066\u20131072.","journal-title":"Neurology"},{"key":"2101389_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/mus.10497","volume":"28","author":"R Schiffmann","year":"2003","unstructured":"Schiffmann R, et al. (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 28:703\u2013710.","journal-title":"Muscle Nerve."},{"key":"2101389_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1529-8027.2011.00365.x","volume":"16","author":"N Uceyler","year":"2011","unstructured":"Uceyler N, et al., (2011) Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. J. Peripher. Nerv. Syst. 16:304\u2013314.","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"2","key":"2101389_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1517\/21678707.2014.899148","volume":"5","author":"BE Smid","year":"2014","unstructured":"Smid BE, Hollak CE. (2014) A systematic review on effectiveness and safety of eliglustat tartrate for type I Gaucher disease. Expert Opin. Orphan Drugs. 5(2):523\u2013529.","journal-title":"Expert Opin. Orphan Drugs"},{"key":"2101389_CR16","volume-title":"Emery and Rimoin\u2019s Principles and Practice of Medical Genetics","author":"RJ Desnick","year":"2013","unstructured":"Desnick RJ, Schuchman EH, Astrin KH, Cheng SH. (2013) Chapter 28 \u2014 Therapies for Lysosomal Storage Diseases. In: Emery and Rimoin\u2019s Principles and Practice of Medical Genetics [Internet]. Rimoin DL, Pyeritz RE, Korf B (eds.) Elsevier Ltd, Waltham (MA). Available from: https:\/\/doi.org\/www.sciencedirect.com\/science\/article\/pii\/B9780123838346000367"},{"key":"2101389_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","volume":"91","author":"KA McEachern","year":"2007","unstructured":"McEachern KA, et al. (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol. Genet. Metab. 91:259\u2013267.","journal-title":"Mol. Genet. Metab."},{"key":"2101389_CR18","doi-asserted-by":"publisher","first-page":"e15033","DOI":"10.1371\/journal.pone.0015033","volume":"5","author":"J Marshall","year":"2010","unstructured":"Marshall J, et al. (2010) Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS One. 5:e15033.","journal-title":"PLoS One"},{"key":"2101389_CR19","unstructured":"Marshall J, et al. (2013) A novel, selective and orally-available glucosylceramide synthase inhibitor for substrate reduction therapy of Fabry disease. Poster session presented at the 63rd Annual Meeting of The American Society of Human Genetics; Oct 22\u201326; Boston, MA. Abstract available from: https:\/\/doi.org\/www.ashg.org\/2013meeting\/abstracts\/fulltext\/f130121098.htm"},{"key":"2101389_CR20","first-page":"A208","volume":"59","author":"AM Wang","year":"1996","unstructured":"Wang AM, et al. (1996) Generation of a mouse model with a-galactosidase A deficiency. Am. J. Hum. Genet. 59:A208.","journal-title":"Am. J. Hum. Genet."},{"key":"2101389_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/sj.mt.6300066","volume":"15","author":"RJ Ziegler","year":"2007","unstructured":"Ziegler RJ, et al. (2007) Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. Mol. Ther. 15:492\u2013500.","journal-title":"Mol. Ther."},{"key":"2101389_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1089\/hum.2008.010","volume":"19","author":"RJ Ziegler","year":"2008","unstructured":"Ziegler RJ, et al. (2008) Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice. Hum. Gene. Ther. 19:609\u2013621.","journal-title":"Hum. Gene. Ther."},{"key":"2101389_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1086\/316953","volume":"68","author":"YA Ioannou","year":"2001","unstructured":"Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. (2001) Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. 68:14\u201325.","journal-title":"Am. J. Hum. Genet."},{"key":"2101389_CR24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0022-2275(20)43007-X","volume":"11","author":"L Coles","year":"1970","unstructured":"Coles L, Hay JB, Gray GM. (1970) Factors affecting the glycosphingolipid composition of murine tissues. J. Lipid. Res. 11:158\u2013163.","journal-title":"J. Lipid. Res."},{"key":"2101389_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1210\/endo-113-1-251","volume":"113","author":"RH McCluer","year":"1983","unstructured":"McCluer RH, Deutsch CK, Gross SK. (1983) Testosterone-responsive mouse kidney glycosphingolipids: developmental and inbred strain effects. Endocrinology. 113:251\u2013258.","journal-title":"Endocrinology"},{"key":"2101389_CR26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-2275(20)43013-5","volume":"11","author":"RJ Desnick","year":"1970","unstructured":"Desnick RJ, Sweeley CC, Krivit W. (1970) A method for the quantitative determination of neutral glycosphingolipids in urine sediment. J. Lipid. Res. 11:31\u201337.","journal-title":"J. Lipid. Res."},{"key":"2101389_CR27","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJM197104082841401","volume":"284","author":"RJ Desnick","year":"1971","unstructured":"Desnick RJ, Dawson G, Desnick SJ, Sweeley CC, Krivit W. (1971) Diagnosis of glycosphingolipidoses by urinary-sediment analysis. N. Engl. J. Med. 284:739\u2013744.","journal-title":"N. Engl. J. Med."},{"key":"2101389_CR28","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/mt.2009.37","volume":"17","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, et al. (2009) Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol. Ther. 17:954\u2013963.","journal-title":"Mol. Ther."},{"key":"2101389_CR29","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","volume":"12","author":"LM Franco","year":"2005","unstructured":"Franco LM, et al. (2005) Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol. Ther. 12:876\u201384.","journal-title":"Mol. Ther."},{"key":"2101389_CR30","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1172\/JCI200316887","volume":"111","author":"F Mingozzi","year":"2003","unstructured":"Mingozzi F, et al. (2003) Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest. 111:1347\u20131356.","journal-title":"J. Clin. Invest."},{"key":"2101389_CR31","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/jgm.901","volume":"8","author":"KA McEachern","year":"2006","unstructured":"McEachern KA, et al. (2006) AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. J. Gene. Med. 8:719\u2013729.","journal-title":"J. Gene. Med."},{"key":"2101389_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","volume":"9","author":"RJ Ziegler","year":"2004","unstructured":"Ziegler RJ, et al. (2004) AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol. Ther. 9:231\u2013240.","journal-title":"Mol. Ther."},{"key":"2101389_CR33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/ijcp.12016","volume":"67","author":"P Kaminsky","year":"2013","unstructured":"Kaminsky P, et al. (2013) Multidimensional analysis of clinical symptoms in patients with Fabry\u2019s disease. Int. J. Clin. Pract. 67:120\u2013127.","journal-title":"Int. J. Clin. Pract."},{"key":"2101389_CR34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ajpath.2014.11.004","volume":"185","author":"DS Bangari","year":"2015","unstructured":"Bangari DS, et al. (2015) alpha-Galactosidase A Knockout Mice: Progressive Organ Pathology Resembles the Type 2 Later-Onset Phenotype of Fabry Disease. Am. J. Pathol. 185:651\u2013665.","journal-title":"Am. J. Pathol."},{"key":"2101389_CR35","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","volume":"119","author":"BL Thurberg","year":"2009","unstructured":"Thurberg BL, et al. (2009) Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation. 119:2561\u20132567.","journal-title":"Circulation"},{"key":"2101389_CR36","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s10545-014-9724-5","volume":"37","author":"JM Itier","year":"2014","unstructured":"Itier JM, et al. (2014) Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J. Inherit. Metab. Dis. 37:1013\u20131022.","journal-title":"J. Inherit. Metab. Dis."},{"key":"2101389_CR37","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jama.2015.459","volume":"313","author":"PK Mistry","year":"2015","unstructured":"Mistry PK, et al. (2015) Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. J. Amer. Med. Assoc. 313:695\u2013706.","journal-title":"J. Amer. Med. Assoc."},{"key":"2101389_CR38","unstructured":"Cox TM, et al. (2015) Eliglustat versus imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. pii:S0140\u20136736(14)61841\u20139."},{"key":"2101389_CR39","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/pgmj.67.788.584","volume":"67","author":"CI Jack","year":"1991","unstructured":"Jack CI, Morris AI, Nasmyth DG, Carroll N. (1991) Colonic involvement in Fabry\u2019s disease. Postgrad. Med. J. 67:584\u2013585.","journal-title":"Postgrad. Med. J."},{"key":"2101389_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/1066896911428737","volume":"19","author":"K Deniz","year":"2011","unstructured":"Deniz K, et al. (2011) Colonic involvement in Fabry disease. Int. J. Surg. Pathol. 19:777\u2013778.","journal-title":"Int. J. Surg. Pathol."},{"key":"2101389_CR41","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","volume":"5","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Schwarz M, Mehta A, Keshav S. (2007) Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin. Gastroenterol. Hepatol. 5:1447\u20131453.","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"2101389_CR42","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/ndt\/gfn058","volume":"23","author":"P Gonzales","year":"2008","unstructured":"Gonzales P, Pisitkun T, Knepper MA. (2008) Urinary exosomes: is there a future? Nephrol. Dial. Transplant. 23:1799\u20131801.","journal-title":"Nephrol. Dial. Transplant."},{"key":"2101389_CR43","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10545-009-1254-1","volume":"32","author":"TW Crosbie","year":"2009","unstructured":"Crosbie TW, Packman W, Packman S. (2009) Psychological aspects of patients with Fabry disease. J. Inherit. Metab. Dis. 32:745\u2013753.","journal-title":"J. Inherit. Metab. Dis."},{"key":"2101389_CR44","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jpeds.2010.11.053","volume":"158","author":"YH Chien","year":"2011","unstructured":"Chien YH, et al. (2011) Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J. Pediatr. 158:1023\u20131027.e1.","journal-title":"J. Pediatr."}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2015.00088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.2119\/molmed.2015.00088\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.crossref.org\/molmed.2015.00088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2015.00088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T19:58:07Z","timestamp":1653076687000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.2119\/molmed.2015.00088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["2101389"],"URL":"https:\/\/doi.org\/10.2119\/molmed.2015.00088","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"14 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}